Cellectar Biosciences, Inc. (CLRB) |
3.11 -0.08 (-2.51%) 04-23 16:00 |
Open: | 3.17 |
High: | 3.2793 |
Low: | 3.11 |
Volume: | 897,171 |
Market Cap: | 100(M) |
PE Ratio: | -1 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 4.17 |
Resistance 1: | 3.71 |
Pivot price: | 3.46 |
Support 1: | 2.96 |
Support 2: | 2.47 |
52w High: | 4.45 |
52w Low: | 1.33 |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
EPS | -3.110 |
Book Value | -0.360 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -144.7 |
Return on Equity (ttm) | -536.8 |
Sun, 14 Apr 2024
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest Update - MarketBeat
Thu, 04 Apr 2024
Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent ... - The Globe and Mail
Fri, 29 Mar 2024
Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven? - Yahoo Finance
Wed, 27 Mar 2024
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 06 Mar 2024
Cellectar Biosciences Inc (CLRB) Stock Gains 5.33% This Week: Is It a Good Pick? - InvestorsObserver
Mon, 04 Mar 2024
Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why - Markets Insider
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |